Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
IntroductionCurrently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-1 (PD-L1) expression (≧50%). Pre-treatment or post...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1308381/full |
| _version_ | 1797404315310096384 |
|---|---|
| author | Takashi Shimizu Takashi Shimizu Eisuke Inoue Ryotaro Ohkuma Ryotaro Ohkuma Shinichi Kobayashi Takuya Tsunoda Satoshi Wada Satoshi Wada Satoshi Wada Satoshi Wada Satoshi Wada |
| author_facet | Takashi Shimizu Takashi Shimizu Eisuke Inoue Ryotaro Ohkuma Ryotaro Ohkuma Shinichi Kobayashi Takuya Tsunoda Satoshi Wada Satoshi Wada Satoshi Wada Satoshi Wada Satoshi Wada |
| author_sort | Takashi Shimizu |
| collection | DOAJ |
| description | IntroductionCurrently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-1 (PD-L1) expression (≧50%). Pre-treatment or post-treatment serum soluble PD-L1 (sPD-L1) has been identified as a potential biomarker for assessing ICI efficacy through fixed-point observations. However, existing studies on sPD-L1 changes have produced inconsistent results or have had sample sizes too small to detect clinically meaningful effect sizes. To elucidate the role of sPD-L1, we conducted a collaborative individual patient data meta-analysis of PD-1 inhibitor treatments.MethodsWe conducted a thorough search of articles in PubMed via Medline, Embase, Scopus, and Cochrane databases from inception to October 20, 2023. Trials were deemed eligible if they contained individual datasets for advanced NSCLC patients, including data on overall survival (OS)/progression-free survival (PFS), as well as pre- and post-treatment sPD-L1 levels after 3-4 cycles of PD-1 inhibitor treatments. Our analysis focused on patients who completed 3-4 cycles of PD-1 inhibitor treatments. The primary outcome measure was OS/PFS, and we assessed changes in sPD-L1 concentration pre- and post-treatment through ELISA analyses.ResultsFrom our search, we identified a potential seven trials, encompassing 256 patients. Among these, two trials with 26 patients met the criteria for inclusion in our primary analyses. Over a median follow-up period of 10 months, pooled univariate analysis revealed that increases in sPD-L1 levels during PD-1 inhibitor treatment were not associated with OS (HR = 1.25; CI: 0.52–3.02)/PFS (HR = 1.42; CI: 0.61–3.30) when compared to cases with sPD-L1 decreases. Subgroup analyses indicated that the impact of sPD-L1 changes on overall mortality/progression-related mortality remained consistent regardless of gender, age, or the type of treatment (nivolumab or pembrolizumab).ConclusionOur findings suggest that changes in sPD-L1 levels during PD-1 inhibitor treatment do not significantly influence the prognosis of advanced NSCLC patients, regardless of gender, age, or treatment type. Continuous monitoring of sPD-L1 may not offer significant advantages compared to fixed-point observations. |
| first_indexed | 2024-03-09T02:53:12Z |
| format | Article |
| id | doaj.art-79df360ee61b4247bc78ebaffe4da883 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-09T02:53:12Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-79df360ee61b4247bc78ebaffe4da8832023-12-05T09:04:51ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-11-011410.3389/fimmu.2023.13083811308381Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysisTakashi Shimizu0Takashi Shimizu1Eisuke Inoue2Ryotaro Ohkuma3Ryotaro Ohkuma4Shinichi Kobayashi5Takuya Tsunoda6Satoshi Wada7Satoshi Wada8Satoshi Wada9Satoshi Wada10Satoshi Wada11Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanShowa University Research Administration Center, Showa University, Tokyo, JapanDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, JapanClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, JapanDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, JapanDepartment of Pharmacology, School of Medicine, Showa University, Tokyo, JapanPharmacological Research Center, Showa University, Tokyo, JapanIntroductionCurrently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-1 (PD-L1) expression (≧50%). Pre-treatment or post-treatment serum soluble PD-L1 (sPD-L1) has been identified as a potential biomarker for assessing ICI efficacy through fixed-point observations. However, existing studies on sPD-L1 changes have produced inconsistent results or have had sample sizes too small to detect clinically meaningful effect sizes. To elucidate the role of sPD-L1, we conducted a collaborative individual patient data meta-analysis of PD-1 inhibitor treatments.MethodsWe conducted a thorough search of articles in PubMed via Medline, Embase, Scopus, and Cochrane databases from inception to October 20, 2023. Trials were deemed eligible if they contained individual datasets for advanced NSCLC patients, including data on overall survival (OS)/progression-free survival (PFS), as well as pre- and post-treatment sPD-L1 levels after 3-4 cycles of PD-1 inhibitor treatments. Our analysis focused on patients who completed 3-4 cycles of PD-1 inhibitor treatments. The primary outcome measure was OS/PFS, and we assessed changes in sPD-L1 concentration pre- and post-treatment through ELISA analyses.ResultsFrom our search, we identified a potential seven trials, encompassing 256 patients. Among these, two trials with 26 patients met the criteria for inclusion in our primary analyses. Over a median follow-up period of 10 months, pooled univariate analysis revealed that increases in sPD-L1 levels during PD-1 inhibitor treatment were not associated with OS (HR = 1.25; CI: 0.52–3.02)/PFS (HR = 1.42; CI: 0.61–3.30) when compared to cases with sPD-L1 decreases. Subgroup analyses indicated that the impact of sPD-L1 changes on overall mortality/progression-related mortality remained consistent regardless of gender, age, or the type of treatment (nivolumab or pembrolizumab).ConclusionOur findings suggest that changes in sPD-L1 levels during PD-1 inhibitor treatment do not significantly influence the prognosis of advanced NSCLC patients, regardless of gender, age, or treatment type. Continuous monitoring of sPD-L1 may not offer significant advantages compared to fixed-point observations.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1308381/fullsoluble PD-L1advanced non-small cell lung cancerPD-1 inhibitorsindividual patient data meta-analysisbiomarker |
| spellingShingle | Takashi Shimizu Takashi Shimizu Eisuke Inoue Ryotaro Ohkuma Ryotaro Ohkuma Shinichi Kobayashi Takuya Tsunoda Satoshi Wada Satoshi Wada Satoshi Wada Satoshi Wada Satoshi Wada Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis Frontiers in Immunology soluble PD-L1 advanced non-small cell lung cancer PD-1 inhibitors individual patient data meta-analysis biomarker |
| title | Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis |
| title_full | Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis |
| title_fullStr | Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis |
| title_full_unstemmed | Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis |
| title_short | Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis |
| title_sort | soluble pd l1 changes in advanced non small cell lung cancer patients treated with pd 1 inhibitors an individual patient data meta analysis |
| topic | soluble PD-L1 advanced non-small cell lung cancer PD-1 inhibitors individual patient data meta-analysis biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1308381/full |
| work_keys_str_mv | AT takashishimizu solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT takashishimizu solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT eisukeinoue solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT ryotaroohkuma solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT ryotaroohkuma solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT shinichikobayashi solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT takuyatsunoda solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT satoshiwada solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT satoshiwada solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT satoshiwada solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT satoshiwada solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis AT satoshiwada solublepdl1changesinadvancednonsmallcelllungcancerpatientstreatedwithpd1inhibitorsanindividualpatientdatametaanalysis |